SSR 125180

Drug Profile

SSR 125180

Alternative Names: SR 125180

Latest Information Update: 23 Feb 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sanofi-Synthelabo
  • Class Obesity therapies
  • Mechanism of Action Cholecystokinin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Obesity

Most Recent Events

  • 23 Feb 2004 Discontinued - Phase-I for Obesity in France (unspecified route)
  • 09 Jun 2003 Phase-I clinical trials in Obesity in France (unspecified route)
  • 20 Jun 2001 Preclinical development for Obesity in France (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top